Gilead Gets Buy, Amgen Holds: Biopharma Calls Roil Markets
Wall Street resorts to fresh coverage on three large cap biopharma names as Jefferies flags Gilead and Amgen while JP...
What is the value of hiring a financial advisor when you're young? Discover how professional guidance can impact your financial journey.
23,649 articlesWall Street resorts to fresh coverage on three large cap biopharma names as Jefferies flags Gilead and Amgen while JP...
Tesla stock has slid about 18% from its December peak as deliveries declined and autonomy safety metrics raise questi...
Discover what to expect from Urban One's 2025 earnings. This guide breaks down revenue drivers, margins, and strategi...
BYD claims a dramatic leap in charging speed that could reshape the EV landscape. This article unpacks what that mean...
Two discount retailers face off for 2026 returns, with Dollar Tree highlighting a store-format push and Dollar Genera...
Amazon launches 1-hour and 3-hour delivery across dozens of U.S. markets, delivering faster options for groceries and...
Investors are watching a handful of tech names retreat despite strong long term potential. This guide explains how be...
Through March 21, 2026, VT is down less than 1% year-to-date while SPY slides about 3%, signaling a shift toward glob...
Gold prices slide as liquidity fades and risk appetite shifts, forcing traders to rethink the king of safe havens and...
Big-cap U.S. stocks are trading at more attractive levels after a year of resilience and rising macro uncertainty. An...
A contrarian take on the tech sell-off. Learn why durable AI and cloud trends could spark a rebound and how to positi...
Celsius Holdings has fallen hard, leaving some investors wondering if a rebound is possible. This guide breaks down t...